Risk-Based Treatment for Non-Rhabdomyosarcoma (Cancer)

What we are studying

Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) are rare tumors and little is known about them. At the present time, doctors do not always know what the best treatment will be for a subject with one of these tumors. Studies done in both children and adults with NRSTS have shown that the amount of treatment a subject needs may be based on the “risk group” of the tumor. This study is being done to find out: if treatment based on each subject’s level of risk will get rid of the tumor and if lessening the treatment for lower risk subjects will decrease the side effects of treatment and still get rid of the tumor.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • All Ages up to 30

Eligibility Criteria

  • Diagnosed with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)

What is involved

  • Participation depends on risk group and treatment arm
  • Follow-Up will last about 10 years

Compensation

None

Contact Information

Study Coordinator
Graham Keyes
Email
grkeyes@wakehealth.edu
Phone
336-716-9027

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.